Heart Disease News and Research

Latest Heart Disease News and Research

New article questions role of amenities in hospital care

From hotel-style room service to massage therapy to magnificent views, hospitals are increasingly touting their luxury services in a bid to gain market share, especially those in competitive urban markets. An important new article, published today in the New England Journal of Medicine, raises crucial questions about the role of amenities in hospital care, explaining that how we decide to value the patient experience can have a significant effect on health care costs.

3 Dec 2010

Moderate consumption of 'energy drinks' can improve people's response time

Moderate consumption of so-called energy drinks can improve people's response time on a lab test measuring behavioral control, but those benefits disappear as people drink more of the beverage, according to a study published by the American Psychological Association.

3 Dec 2010

Rcadia's COR Analyzer System effective to rule-out coronary artery disease

Physicians at Thomas Jefferson University Hospital reported today on results of a study demonstrating the potential for fully automated interpretation of coronary CT angiography (cCTA) by Rcadia's COR Analyzer® System to safely rule out coronary artery disease (CAD) in the major coronary arteries as well as branch vessels.

3 Dec 2010

Healthy lifestyle choices, emergency room interventions can help prevent first-time strokes

Healthy lifestyle choices and emergency room interventions can help prevent first-time strokes, according to revised American Heart Association/American Stroke Association guidelines.

3 Dec 2010

CRT therapy is cost-effective for symptomatic heart failure patients: REVERSE trial

Medtronic, Inc. announced findings from an economic sub-study of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial published in the European Heart Journal demonstrating for the first time that cardiac resynchronization therapy (CRT) is cost-effective in mildly symptomatic heart failure (HF) patients.

3 Dec 2010

Cardiac surgeons are trying innovative approaches to traditional open heart surgery

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, cardiac surgeons are trying new innovative approaches to traditional open heart surgery as they try to make coronary artery bypass graft (CABG) procedures less invasive where possible.

3 Dec 2010

Scripps scientists find way to transform mature human cells into stem cells

Scripps Research Institute scientists have made a significant leap forward in the drive to find a way to safely reprogram mature human cells and turn them into stem cells, which can then change into other cell types, such as nerve, heart, and liver cells. The ability to transform fully mature adult cells such as skin cells into stem cells has potentially profound implications for treating many diseases.

3 Dec 2010

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

The discovery by UCLA biochemists of a new method for preventing oxidation in the essential fatty acids of cell membranes could lead to a new class of more effective nutritional supplements and potentially help combat neurodegenerative disorders such as Parkinson's disease and perhaps Alzheimer's.

3 Dec 2010

Arthritis drug reduces incidence of non-melanoma skin cancers

A widely-used arthritis drug reduces the incidence of non-melanoma skin cancers - the most common cancers in humans - according to a study published this week in the Journal of the National Cancer Institute. The COX-2 inhibitor celecoxib (brand name Celebrex), which is currently approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain in adults led to a 62 percent reduction in non-melanoma skin cancers, which includes basal cell carcinomas and squamous cell carcinomas.

3 Dec 2010

Sentara Heart Hospital commences procedures in AtriCure DEEP AF feasibility trial

Sentara Heart Hospital is breaking new ground in cardiac care and treatment. Surgeons and Cardiologists at Sentara Heart Hospital are first to begin enrolling and performing trial cases in the AtriCure DEEP AF feasibility trial. The first procedure in the country was performed in a new, state-of-the-art hybrid operating room at Sentara Heart Hospital by Jonathan Philpott, M.D., Director of the Sentara Atrial Fibrillation Surgery Program, Ian Woollett, M.D., and John Onufer, M.D., Medical Director of Cardiac Electrophysiology.

3 Dec 2010

Dysfunction in blood vessels plays a role in Alzheimer's disease development

A dysfunction in the lining of blood vessels that is linked to cardiovascular illness also appears to play a role in the development of Alzheimer's disease, according to a study published in Circulation Research: Journal of the American Heart Association.

3 Dec 2010

AHA: Incidence of hospitalization for heart valve diseases rises in New York

The incidence of hospitalization and treatment for heart valve diseases in New York State has constantly and progressively risen since the early 1980s, according to research presented at the recent meeting of the American Heart Association (AHA) by SUNY Downstate Medical Center. The study results were published in a supplement to the AHA journal, Circulation.

3 Dec 2010

Doctors still prescribe higher-dose menopausal hormone therapy pills

Doctors across the country are still prescribing higher-dose menopausal hormone therapy pills, despite clinical evidence that low doses and skin patches work just as well and carry fewer health risks. That's what researchers at the Stanford University School of Medicine found in a study that will be published online Dec. 2 in Menopause: The Journal of the North American Menopause Society.

3 Dec 2010

Alcohol drinking pattern impacts coronary heart disease

A fascinating study published in the BMJ shows that although the French drink more than the Northern Irish each week, as they drink daily, rather than more on less occasions, the French suffered from considerably less coronary heart disease than the Northern Irish.

3 Dec 2010

AtriCure initiates enrollment in DEEP AF feasibility trial

AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, announced initial patient enrollment in its DEEP AF feasibility trial. The first procedure was performed in a new, state-of-the-art hybrid room at Sentara Norfolk General Hospital in Norfolk, Virginia by Jonathan Philpott, M.D., Director of the Sentara Atrial Fibrillation Surgery Program, Ian Woollett, M.D., and John Onufer, M.D., Medical Director of Cardiac Electrophysiology.

3 Dec 2010

BMEYE signs licensing agreement with PULSION Medical Systems

BMEYE's Breakthrough Totally Noninvasive Blood Pressure and Cardiac Output Technology Will be Incorporated Into PULSION's Next Generation Patient Monitors

3 Dec 2010

New study offers hope for children with MPS I genetic disorder

A new study offers hope for children born with a rare genetic disease, according to a paper published by the American Association for the Advancement of Science.

3 Dec 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer.

3 Dec 2010

Arteriocyte launches Stem Cell Expansion System for research use

Arteriocyte, Inc., a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies announced today the launch of its first commercially available Stem Cell Expansion System for research use.

2 Dec 2010

FDA approves IDE application to initiate Tryton Side Branch Stent System for coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced U.S. Food and Drug Administration (FDA) conditional approval for an Investigational Device Exemption (IDE) application to initiate the pivotal trial to evaluate the Tryton Side Branch Stent System for the treatment of coronary artery disease.

2 Dec 2010